Merrill Lynch Sale of GM Notes Results in $1.9M Fine Over Unfair Pricing

A financial industry oversight group has fined Merrill Lynch $1.9 million for purchasing General Motors notes at unfair prices, also ordering the company to pay $540,000 in restitution to customers. 

The Financial Industry Regulatory Authority (FINRA) determined that Merrill Lynch bought Motors Liquidation Company Senior Notes from retail customers at discounts ranging from 5.3% to 61.5% below market price, then sold them to other brokers and dealers at market prices. Most had markdowns of more than 10% when the company purchased them.

The judgment and fines against Merrill Lynch were announced by FINRA in a December 16 press release, indicating that the GM notes, sold by the auto maker before its bankruptcy, were purchased from customers at unfair prices. FINRA found 716 instances where customers were not paid enough for the GM notes.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The restitution, which includes interest, is to be paid to the customers who sold Merrill Lynch’s Global Banking & Markets Credit Trading Desk the notes at unfair prices.

In addition to the unfair pricing charge, FINRA also determined that the problems occurred because the company failed to adequately supervise the credit desk, and did not properly review its transactions. FINRA has ordered the company to create three reports over the next 18 months detailing its system of supervising the pricing of retail customer transactions made by its credit desk.

“We expect firms to adhere to their fair pricing obligations to customers when transacting in lower-priced or distressed securities,” said Thomas Gira, FINRA Executive Vice President and Head of Market Regulation. “Even after factoring in the nature of the market for these types of instruments, the markdowns charged were simply unacceptable, as was Merrill Lynch’s failure to conduct post-trade fair pricing or best execution reviews for customer transactions executed on the Credit Desk.”

Merrill Lynch neither admitted to nor denied the charges, FINRA officials said. The company has said that it has already taken disciplinary action and is addressing the problems that led to the marked down purchases.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted 2 days ago)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 3 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 4 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.